A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With an Open-Label Safety Extension

Trial Profile

A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With an Open-Label Safety Extension

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Omiganan (Primary)
  • Indications Rosacea
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Cutanea Life Sciences
  • Most Recent Events

    • 07 May 2018 Status changed from active, no longer recruiting to completed.
    • 23 Jan 2018 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
    • 11 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top